US 11,925,654 B2
Esters of 2-deoxy-monosaccharides with anti proliferative activity
Waldemar Priebe, Houston, TX (US); Marcin Cybulski, Warsaw (PL); Izabela Fokt, Houston, TX (US); Stanislaw Skora, Houston, TX (US); Charles Conrad, Austin, TX (US); and Timothy Madden, Sugar Land, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Jun. 4, 2021, as Appl. No. 17/339,028.
Application 17/339,028 is a continuation of application No. 16/229,338, filed on Dec. 21, 2018, granted, now 11,026,960.
Application 16/229,338 is a continuation of application No. 14/782,521, granted, now 10,201,554, issued on Feb. 12, 2019, previously published as PCT/US2014/032942, filed on Apr. 4, 2014.
Claims priority of provisional application 61/809,110, filed on Apr. 5, 2013.
Prior Publication US 2022/0023326 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7024 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/7024 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01)] 32 Claims
 
1. A method of treating a proliferative disease chosen from squamous cell carcinoma and lung adenocarcinoma by inhibiting glycolysis in glycolytic tumor cells in a patient in need thereof comprising administering a therapeutically effective amount of one or more compounds of the Formula I:

OG Complex Work Unit Chemistry
or a salt, ester or prodrug thereof, wherein:
each R1, R2, R3 and R4 are independently H, or COR5;
at least one of R1, R2, R3 and R4 is COR5; and
each R5 is independently selected from the group C3-C10 straight- or branched-chain alkyl, C4-C10 alkylcycloalkyl, and C3-C10 cycloalkyl.